Using data and samples from the WHI, we explored the association between ANA and anti-TAA antibodies in baseline sera obtained from women who later developed breast cancer (i.e., “cases,” diagnosed an average of 7 years after serum collection), and in age and ANA-matched “controls” who did not develop breast cancer during follow-up. The gene discussed is BTG3; the disease is breast cancer.